Pull to refresh
Logo
Blood pressure stays lower two years after a short course of an aldosterone drug

Blood pressure stays lower two years after a short course of an aldosterone drug

New Capabilities

A 14-patient follow-up suggests a finite treatment could reverse a common hormonal cause of hypertension, but larger trials are needed.

Overview

Updated 35 minutes ago

Fourteen people with primary aldosteronism took an experimental aldosterone-blocking drug for 6 to 12 months. Two years after stopping, their systolic blood pressure averaged 25 points lower and a hormone marker of excess aldosterone was 99% below baseline.

The result suggests a finite course might reset the adrenal nodules that drive the condition, not just control blood pressure. The study is small and retrospective, so it does not prove a cure; a larger prospective trial called ELIXIR is now testing the idea.

Why it matters

If the result holds, some people with a hormone-driven form of high blood pressure could stop daily pills after a finite course.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

25 mmHg
Systolic blood pressure reduction
Average at two years after stopping, versus before treatment.
99.2%
Aldosterone-to-renin ratio reduction
Median at follow-up versus baseline in nine patients.
14
Participants in follow-up
All had primary aldosteronism and took the drug for 6 to 12 months.
3 of 13
Normal blood pressure off drugs
Three participants among 13 with blood pressure records.
6–12 months
Treatment course
Length of extended aldosterone synthase inhibition.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

2005 November 2026

4 events Latest: 6 days ago
Tap a bar to jump to that date
  1. Queen Mary announces larger ELIXIR trial

    Latest Research

    The university says the prospective trial will test durable cure and image the adrenal glands.

  2. Follow-up finds benefits persist after treatment stops

    Research

    NEJM correspondence reports 14 patients with blood pressure 25 points lower and hormone marker 99% lower up to two years later.

  3. First trial of aldosterone synthase inhibitor in primary aldosteronism

    Research

    Queen Mary-led study tested the drug class in people with the condition.

  4. Mouse experiment points to aldosterone synthase

    Research

    Deleting the gene for aldosterone synthase caused aldosterone-producing cells to disappear in mice.

Scenarios

1

ELIXIR confirms durable remission in a larger trial

Possible Resolves by End of 2030

Discussed by: Queen Mary researchers and the NEJM authors

The prospective ELIXIR trial will treat more patients and use molecular imaging to see whether aldosterone-producing cells disappear. A positive result would turn a small retrospective signal into evidence that a finite course can reset the adrenal glands.

2

Larger trial fails to replicate the durable remission

Possible Resolves by End of 2030

Discussed by: Clinicians who note the study's small size and retrospective design

The 14-patient follow-up had no control group and relied on routine records. If a controlled trial finds hormone levels rebound after treatment stops, the finite-course idea would remain experimental.

3

Adrenal surgery remains the standard durable cure

Possible Resolves by End of 2028

Discussed by: Endocrine surgeons and guideline panels

Adrenalectomy removes the overactive gland and can cure primary aldosteronism, but it requires invasive testing and surgery. If drug remission data stay preliminary, guidelines may keep surgery as the main durable option.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2005

Mouse knockout experiment (2005)

Researchers deleted the gene responsible for producing aldosterone synthase in mice. The cells that make aldosterone disappeared.

Then

The result suggested that blocking the enzyme for a long time might have the same effect in people.

Now

It became the scientific basis for testing extended aldosterone synthase inhibition as a possible cure.

Why this matters now

The 2026 follow-up is the first human test of that prediction.

2025

First-in-human aldosterone synthase inhibitor trial (2025)

Queen Mary researchers led the first study of this drug class in people with primary aldosteronism, published in the New England Journal of Medicine.

Then

The trial established that the drug could lower aldosterone production.

Now

It gave researchers a cohort to follow after treatment stopped.

Why this matters now

The 2026 correspondence reports what happened to 14 of those patients up to two years later.

Sources

(2)